Saturday, July 11, 2026

Patent intelligence · US

US 6783763

Polyepitopic proteinic fragments of the E6 and E7 HPV proteins, production and use thereof in vaccines

expired A61KA61K38/00A61K39/00A61P
Status expired
Linked drugs 1
Pipeline programs 6
Years to expiry 0
Applicant portfolio 133
Patent details — US 6783763
Jurisdiction
US
Status
expired
Grant date
Aug 31, 2004
Expiration
Aug 26, 2024
Claims
4
CPC classes
A61K, A61K38/00, A61K39/00, A61P
View on Google Patents ↗

Quick answer

US 6783763 (Polyepitopic proteinic fragments of the E6 and E7 HPV proteins, production and use thereof in vaccines) is held by Peptide Immune Ligands. Status: expired. Granted Aug 31, 2004. Expires Aug 26, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
4
CPC classes
A61K, A61K38/00, A61K39/00, A61P, A61P31/18, A61P37/02

More from Peptide Immune Ligands

Related pharmaceutical patents in our USPTO index.

  1. US 12403087

    Topical antiviral compositions, delivery systems, and methods of using the same

    Ligand Pharmaceuticals Incorporated · Expires Aug 28, 2045

    granted
  2. US 12319651

    Crystalline forms and methods of producing crystalline forms of a compound

    Ligand Pharmaceuticals Incorporated · Expires May 29, 2045

    granted
  3. US 12246014

    Azetidine derivatives

    Ligand UK Development Limited · Expires Mar 6, 2045

    granted
  4. US 12208071

    Glucagon receptor antagonists

    Ligand Pharmaceuticals Incorporated · Expires Jan 23, 2045

    granted
  5. US 12123012

    Methods and compositions for nucleic acid and protein payload delivery

    LIGANDAL, INC. · Expires Oct 17, 2044

    granted
  6. US 11970482

    Acetal compounds and therapeutic uses thereof

    Ligand Pharmaceuticals Incorporated · Expires Apr 25, 2044

    granted
  7. US 11952364

    TRK inhibitors useful as anticancer drugs

    TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED · Expires Apr 4, 2044

    granted
  8. US 11773110

    Heterocycle amines and uses thereof

    Ligand Pharmaceuticals Incorporated · Expires Sep 28, 2043

    granted

Frequently asked questions

What is US patent 6783763?

US 6783763 (Polyepitopic proteinic fragments of the E6 and E7 HPV proteins, production and use thereof in vaccines) is held by Peptide Immune Ligands. Status: expired. Granted Aug 31, 2004. Expires Aug 26, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6783763?

Peptide Immune Ligands is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 133 pharmaceutical patents for this assignee.

When does US 6783763 expire?

Our index shows an expiration date of Aug 26, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.